Aspire Biopharma Holdings (ASBP) Receivables - Other (2024)

Aspire Biopharma Holdings' (ASBP) quarterly Receivables - Other came in at $36503.0 in Q4 2024, up 45.81% on a QoQ basis from $25034.0 in Q3 2024.

Aspire Biopharma Holdings (ASBP) Receivables - Other (2024) Analysis & Trends

Aspire Biopharma Holdings (ASBP) has 1 years of Receivables - Other data on file, last reported at $36503.0 in Q4 2024.

On a quarterly basis, Receivables - Other changed N/A year-over-year to $36503.0 in Q4 2024; TTM through Dec 2024 was $36503.0, a N/A change from a year earlier, with the FY2024 full-year figure at $36503.0, changed N/A from the prior year.
Receivables - Other for Q4 2024 stood at $36503.0, up from $25034.0 in the prior quarter.
Over the last five years, Receivables - Other for ASBP reached as high as $299921.0 in Q2 2024 and fell as low as $25034.0 in Q3 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	66,921.77 Bn	66,921.49 Bn	-
2	Nanobiotix	1,933.35 Bn	1,933.29 Bn	-
3	Akari Therapeutics	1,063.56 Bn	1,063.56 Bn	-
4	BeOne Medicines	468.54 Bn	463.75 Bn	1.35 Bn
5	Vertex Pharmaceuticals	123.45 Bn	116.20 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	70.42 Bn	61.67 Bn	3.31 Bn
7	Belite Bio	63.57 Bn	63.57 Bn	-
8	Argenx Se	55.83 Bn	50.65 Bn	1.41 Bn
9	Alnylam Pharmaceuticals	37.75 Bn	34.74 Bn	959.66 Mn
10	Aspire Biopharma Holdings	1.10 Mn	-722,113.72	5,750.00

Download Data